Physician profile
Jaime Robledo
NPI 1942352604
$4,842.84
in general payments reported to CMS, 2019-2025
27 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $136 · 2021: $1,321 · 2022: $1,504 · 2023: $570 · 2024: $413 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $980.91 | 2019-2024 | Senza |
| Nalu Medical, INC. | $718.05 | 2021-2022 | |
| Spinal Simplicity, LLC | $643.81 | 2022 | |
| Medtronic, INC. | $523.52 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Biotronik Nro, INC. | $321.14 | 2024-2025 | Prospera |
| Si-Bone, INC. | $257.34 | 2019-2023 | |
| Intrinsic Therapeutics | $225.68 | 2022-2023 | Barricaid Acd (Annular Closure Device) |
| Boston Scientific Corporation | $211.67 | 2019-2025 | General - Pain Management |
| Genesys Orthopedics Systems, L.L.C. | $198.82 | 2021 | |
| Collegium Pharmaceutical, INC. | $172.99 | 2019-2023 | Belbuca |
| Forte Bio-Pharma LLC | $92.32 | 2022-2023 | Prolate, Nalocet |
| Spr Therapeutics, INC | $85.47 | 2023 | Sprint Pns System |
| Vertos Medical, INC. | $68.92 | 2022-2024 | Mild Device Kit |
| Globus Medical, INC. | $67.97 | 2025 | Senza |
| Biodelivery Sciences International, INC. | $49.90 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.28 | 2019-2020 | |
| Mml US, INC. | $28.34 | 2023 | Reactiv8 |
| Abbott Laboratories | $23.75 | 2022 | |
| Pfizer INC. | $19.65 | 2021 | |
| Stimwave Technologies Incorporated | $18.92 | 2020 | |
| Sentynl Therapeutics, INC. | $16.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2019 | |
| Ibsa Pharma INC. | $15.02 | 2023 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $14.37 | 2019 | |
| Redhill Biopharma INC. | $14.10 | 2021 | |
| Bioventus LLC | $11.58 | 2019 | |
| Relievant Medsystems, INC. | $10.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Robledo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.